On Friday, Calumet earned an upgrade to its Relative Strength (RS) Rating, from 68 to 82.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
Calumet is not currently near a potential buy zone. See if the stock goes on to build a chart pattern that could kick off a new price move.
Calumet showed 0% EPS growth in the latest quarterly report. Sales rose -1%. The company is expected to report its latest earnings and sales numbers on or around Aug. 8.
Calumet earns the No. 18 rank among its peers in the Oil & Gas-Refining/Marketing industry group. UGI, Targa Resources and Global Partners are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
